Ironwood Pharmaceuticals
company in Cambridge, United States
IRWD Nasdaq
ISIN US46333X1081 SEC CIK 1446847 LEI 549300PC8MR6QHH6P296
Follow Ironwood Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$133M
+9% vs same quarter last year
Net income
$59.8M
+49.3% vs same quarter last year
EPS, diluted
$0.36
+56.5% vs same quarter last year
Operating cash flow
$67.4M
+41.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $296.2M | $24M |
| FY24 | $351.4M | $880K |
| FY23 | $442.7M | −$1B |
| FY22 | $410.6M | $175.1M |
| FY21 | $413.8M | $528.4M |
| FY20 | $389.5M | $106.2M |
| FY19 | $428.4M | $21.5M |
| FY18 | $346.6M | −$282.4M |
| FY17 | $298.3M | −$116.9M |
| FY16 | $274M | −$81.7M |
| FY15 | $149.6M | −$142.7M |
| FY14 | $76.4M | −$189.6M |
| FY13 | $22.9M | −$272.8M |
| FY12 | $150.2M | −$72.6M |
| FY11 | $65.9M | −$64.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 33.3% | 8.1% |
| FY24 | - | 26.5% | 0.3% |
| FY23 | - | −213.5% | −233% |
| FY22 | - | 61% | 42.6% |
| FY21 | - | 56.1% | 127.7% |
| FY20 | 99.2% | 36.7% | 27.3% |
| FY19 | 94.4% | 28% | 5% |
| FY18 | 90.6% | −43.5% | −81.5% |
| FY17 | 93.6% | −5.2% | −39.2% |
| FY16 | 99.3% | −18.9% | −29.8% |
| FY15 | 100% | −68.3% | −95.4% |
| FY14 | 93.1% | −221.6% | −248.1% |
| FY13 | 68.5% | −1101.4% | −1192.3% |
| FY12 | 99.4% | −48.4% | −48.3% |
| FY11 | - | −100.4% | −98.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $127M |
| FY24 | $103.4M |
| FY23 | $183.2M |
| FY22 | $273.6M |
| FY21 | $261.6M |
| FY20 | $167M |
| FY19 | $3.5M |
| FY18 | −$71.2M |
| FY17 | −$103.6M |
| FY16 | −$30.1M |
| FY15 | −$111M |
| FY14 | −$159.1M |
| FY13 | −$282.9M |
| FY12 | −$83.6M |
| FY11 | −$84.9M |
- Ironwood Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Ironwood Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 8.1% | −30.6% |
| FY24 | 0.3% | −47% |
| FY23 | −233% | −58% |
| FY22 | 42.6% | −80.4% |
| FY21 | 127.7% | −71.8% |
| FY20 | 27.3% | −62.2% |
| FY19 | 5% | −46.2% |
| FY18 | −81.5% | −49.6% |
| FY17 | −39.2% | −45.9% |
| FY16 | −29.8% | −36% |
| FY15 | −95.4% | −37.8% |
| FY14 | −248.1% | −35.5% |
| FY13 | −1192.3% | −37.1% |
| FY12 | −48.3% | −29.1% |
| FY11 | −98.5% | −27.9% |